| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-09-13 | Pharming (The Netherlands) Santarus (USA) |
Rhucin® (recombinant human C1 inhibitor; Ruconest® in Europe) / acute angioedema attacks in patients with Hereditary Angioedema (HAE) and other future indications |
commercialization/ distribution |
See details |
| 2010-09-13 | Pharming (The Netherlands) Santarus (USA) |
Rhucin® (recombinant human C1 inhibitor; Ruconest® in Europe) / acute angioedema attacks in patients with Hereditary Angioedema (HAE) and other future indications |
commercialization/ distribution |
See details |
| 2010-09-10 | Galapagos (Belgium) Genentech (USA) |
drug discovery programs that utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech. |
R&D other |
See details |
| 2010-09-09 | Atheris Laboratories (Switzerland) Bachem (Switzerland) |
Melusine® libraries (natural products isolated from animal venoms, mainly peptide toxins) |
R&D development other |
See details |
| 2010-09-09 | Shire Pharmaceuticals (UK) Acceleron Pharma (USA) |
activin receptor type IIB (ActRIIB) class of molecules including ACE-031 / Duchenne Muscular Dystrophy |
R&D licensing commercialization/ distribution development |
See details |
| 2010-09-08 | Galapagos (Belgium) GSK (UK) |
GSK research centre in Zagreb This center was GSK's Macrolide Center of Excellence for Drug Discovery |
R&D other |
See details |
| 2010-09-08 | Lonza (Switzerland) GSK (UK) |
Five monoclonal antibodies / undisclosed | manufacturing |
See details |
| 2010-09-07 | reMYND (Belgium) Roche (Switzerland) |
small molecule programmes targeting á-synuclein and tau related pathologies / Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders |
R&D licensing commercialization/ distribution development |
See details |
| 2010-09-06 | Stallergènes (France) Shionogi (Japan) |
Actair® house dust mite tablets and Japanese cedar pollen tablets These two immunotherapy tablets are included in Stalair®, the pharmaceutical and clinical development program for immunotherapy tablets being implemented by Stallergenes with a view to obtaining marketing authorizations for pharmaceutical products in Europe and in other strategic markets. The three other development programs are Oralair® (grass pollen), r Bet v 1 (birch pollen recombinant allergen), and ragweed pollen. / allergy |
commercialization/ distribution development marketing/ promotion |
See details |
| 2010-09-03 | Ipsen (France) Santhera Pharmaceuticals (Switzerland) |
Fipamezole (antagonist of the adrenergic alpha-2 receptor) / levodopa-induced dyskinesia in Parkinson’s Disease |
commercialization/ distribution development |
See details |
| 2010-09-02 | Morphosys (Germany) Absynth (UK) |
novel infectious disease targets / Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). | R&D licensing other |
See details |
| 2010-08-31 | BTG (UK) Nycomed USA |
Antivenom serum CroFab®(Crotalidae Polyvalent Immune Fab) Antidigoxin antibody DigiFab® (Digoxin Immune Fab) / digoxin toxicity or overdose |
commercialization/ distribution marketing/ promotion |
See details |
| 2010-08-30 | Kythera Biopharmaceuticals (USA) Intendis (Bayer HealthCare’s Dermatology Unit - Germany) |
ATX-101 This adipolytic agent is based on an undisclosed well-studied endogenous molecule with unique features including selectivity for adipocytes and rapid clearance. It has been designed to reduce small volumes of facial fat through aesthetics’ applications first-in-class injectable drug being studied for the reduction of small volumes of fat, including submental fat. / reduction of small localized volumes of fat, including submental fat (under the chin). |
licensing |
See details |
| 2010-08-27 | Basilea Pharmaceutica (Switzerland) Actelion (Switzerland) |
Toctino® (alitretinoin) / severe chronic hand eczema unresponsive to potent topical corticosteroids |
commercialization/ distribution |
See details |
| 2010-08-25 | TiGenix (Belgium) Catholic University Leuven (Belgium) Ghent University (Belgium) Therosteon (The Netherlands) consortium of investors |
disease modifying drugs / bone and joint diseases |
other |
See details |
